Alembic receives USFDA final approval for Nifedipine Extended-Release Tablets
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The approval further strengthens the Potassium Chloride franchise for the company.
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults.
Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery.
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Subscribe To Our Newsletter & Stay Updated